Prevention    Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation, 2010. 121(9): p. 1069-77. S. Mora, et al., Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial Am Heart J, 2009. 157(5): p. 913-8. A. S. Adabag, et al., Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation, 2009. 119(22): p. 2877-85. J. H. Alexander, et al., Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT) Eur Heart J, 2009. 30(13): p. 1621-6. C. J. Borleffs, et al., Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with non-ischaemic or ischaemic heart disease Eur Heart J, 2009. C. J. Borleffs, et al., Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter Circulation, 2009. 120(13): p. 1174-80. S. J. Connolly, et al., The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention J Am Coll Cardiol, 2009. 53(6): p. 471-9. O. Costantini, et al., Additional prognostic value of physical examination, exercise testing, and arterial ultrasonography for coronary risk assessment in primary prevention Am Heart J, 2009. 158(5): p. 845-51. M. Cournot, et al., Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol, 2009. 104(6): p. 829-34. Y. Cui, et al., Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial J Am Coll Cardiol, 2009. 54(20): p. 1837-46. C. Daubert, et al., Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? Am Heart J, 2009. 158(2): p. 224-9. S. L. Daugherty, et al., Valsartan for prevention of recurrent atrial fibrillation N Engl J Med, 2009. 360(16): p. 1606-17. M. Disertori, et al., Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials Circulation, 2009. 120(20): p. 2006-11. J. W. Eikelboom, D. J. Quinlan and M. O'Donnell, Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Circulation, 2010. 121(1): p. 143-50. B. M. Everett, et al., A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study Eur Heart J, 2009. 30(22): p. 2758-67. M. Gasparini, et al., A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med, 2009. 360(18): p. 1851-61. R. J. Glynn, et al., Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial) Am J Cardiol, 2009. 103(1): p. 41-5. I. Goldenberg, et al., Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention Circulation, 2009. 119(6): p. 902-7. W. S. Harris, et al., Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation Circ Cardiovasc Interv, 2009. 2(4): p. 294-301. C. Herdeg, et al., Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India Circulation, 2009. 119(14): p. 1950-5. R. Joshi, et al., Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population Circulation, 2009. 120(10): p. 835-42. W. C. Levy, et al., Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Eur Heart J, 2009. 30(23): p. 2897-907. G. Y. Lip, et al., Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study J Am Coll Cardiol, 2009. 53(11): p. 931-5. E. D. Michos and R. S. Blumenthal, Studies examine inflammatory biomarker in prevention and prediction of heart disease JAMA, 2009. 301(1): p. 23-4. M. Mitka, Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide J Am Coll Cardiol, 2009. 53(12): p. 1040-6. S. Morikawa, et al., Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial Am Heart J, 2009. 158(3): p. 335-341 e3. D. A. Morrow, et al., Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med, 2009. 361(14): p. 1329-38. A. J. Moss, et al., The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project Am Heart J, 2009. 157(4): p. 709-15 e1. S. Niu, et al., Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Eur Heart J, 2009. 30(10): p. 1245-53. J. P. Piccini, J. S. Berger and C. M. O'Connor, Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) J Am Coll Cardiol, 2009. 54(13): p. 1154-61. N. R. Poulter, et al., Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study Am Heart J, 2009. 158(2): p. 163-169 e1-3. C. M. Pratt, et al., Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial Heart, 2009. 95(6): p. 468-75. J. Redfern, et al., Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention J Am Coll Cardiol, 2009. 54(14): p. 1238-45. J. J. Regieli, et al., The JUPITER trial: results, controversies, and implications for prevention Circ Cardiovasc Qual Outcomes, 2009. 2(3): p. 279-85. P. M. Ridker, Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes, 2009. 2(6): p. 616-23. P. M. Ridker, et al., Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study Circ Cardiovasc Qual Outcomes, 2009. 2(4): p. 297-304. D. E. Singer, et al., Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation Am Heart J, 2009. 157(6): p. 1064-73. S. V. Sorensen, et al., Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation Catheter Cardiovasc Interv, 2009. 75(3): p. 317-325. S. Stojkovic, et al., Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease Am J Cardiol, 2010. 105(3): p. 288-92. A. Toso, et al., Incidence of Left Ventricular Function Improvement After Primary Prevention ICD Implantation for Non-Ischemic Dilated Cardiomyopathy: A Multicenter Experience Heart, 2009. A. Verma, et al.,